logo
logo
Sign in

Hepatitis Drug Demand Rising due to Efforts of International Agencies

avatar
Industrytrends2
Hepatitis Drug Demand Rising due to Efforts of International Agencies

Hepatitis is a common condition around the world that most-prominently causes the liver to swell. There are several risk factors for this condition, including alcohol and drug usage and several infections. However, the most-common cause is the five hepatitis viruses: A, B, C, D, and E, themselves. These viruses can be transmitted into the host via contaminated food and water, infected blood and semen (via sex), unsterilized medical equipment, such as needles and catheters, and in utero.


Mostly, the condition is acute and the symptoms mild, generally consisting of yellow skin, urine, and sclera (jaundice); fever, body ache, loss of appetite, and malaise. However, chronic hepatitis can lead to liver cirrhosis and even liver cancer; therefore, the awareness on catching the condition early and effectively treating it is rising. As per P&S Intelligence, due to such factors, the hepatitis drugs market value is predicted to increase sharply in the next few years.


Additionally, several international and national agencies around the world are working to make people aware of the different forms of the disease and increase the access to timely diagnosis and quality care. For instance, the WHO recognizes July 28th as World Hepatitis Day and conducts awareness campaigns. Moreover, it launched the Global Health Sector Strategy on Viral Hepatitis, 2016–2021 in May 2016, under which it aims to reduce the number of new hepatitis cases by 90% and the number of deaths by 65% by 2030. Similarly, May is recognized as Hepatitis Awareness Month in the U.S., wherein similar activities are conducted.


Of all these types of viral hepatitis infections, the demand for drugs has been the highest for hepatitis C. This is because acute forms of all these diseases do not require treatment, and only the chronic forms do. Hepatitis A and E rarely transition into chronic conditions, whereas only 10–40% of the people with hepatitis B actually require hospitalization. Additionally, by treating hepatitis B, hepatitis D is also treated and its risk reduced, as the hep D virus cannot replicate inside the body without the hep B virus. Hep C, on the other hand, often transitions into a chronic condition, ultimately leading to cirrhosis liver cancer, and hepatic failure; therefore, the idea behind the treatment of hep C is always a complete cure.


North America has been the most-productive hepatitis drugs market till now because it accounts for the most-advanced healthcare infrastructure and easy access to treatment. Additionally, the geriatric population (65 and above age group) in the region is set to cross 96.2 million by 2050 from 59.9 million in 2019, according to the World Population Ageing 2019 report of the United Nations (UN). Owing to their weakened immune system, the elderly become easy hosts for the hepatitis virus. Additionally, they need more-extensive care than the younger people, which is why they account for high hospitalization rates.


Hence, with the growing prevalence of hepatitis infections, the demand for the associated drugs will continue to surge.


collect
0
avatar
Industrytrends2
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more